Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CSTB
REST API REST API
Homo sapiens
CSTB is differentially expressed in 305 experiments: 141 organism parts: lung, tonsil, ... (139 more);, 172 disease states: normal, acute myeloid leukemia, ... (170 more);, 96 cell types 398 cell lines 39 compound treatments and 77 other conditions.
Synonyms EPM1, CST6, PME, STFB
Orthologs CSTB (Gallus gallus)   si:ch211-161h7.6 (Danio rerio)   zgc:56530 (Danio rerio)   CSTB (Bos taurus)   CSTB (Bos taurus)   zgc:153129 (Danio rerio)   ENSBTAG00000009073 (Bos taurus)   Cstb (Mus musculus)   Cstb (Rattus norvegicus)   ENSXETG00000032236 (Xenopus laevis)   CSTB (Canis familiaris)   (Compare orthologs)
InterPro Term Prot_inh_cystat, Prot_inh_stefinA
Gene Ontology Term protein binding, cytoplasm, negative regulation of endopeptidase activity, intracellular, adult locomotory behavior, nucleus, cysteine-type endopeptidase inhibitor activity, endopeptidase inhibitor activity, nucleolus, regulation of apoptosis, protease binding, negative regulation of peptidase activity
UniProt Accession Q76LA1, P04080
Gene-Disease Assocation MYOCLONIC EPILEPSY OF UNVERRICHT AND LUNDBORG
Search EB-eye ENSG00000160213
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, E-GEOD-18105, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (43 experiments)

Factor Value U/D Experiments
SW480
3
E-MEXP-1014, E-MTAB-37, E-GEOD-2509
HCC1937
2
E-MTAB-37, E-MTAB-62
AGS
2
E-MTAB-37, E-GEOD-15460
DU145
2
E-GEOD-17482, E-GEOD-20089
HCC38
2
E-MTAB-62, E-MTAB-37
LNCaP
2
E-GEOD-14990, E-GEOD-847
392 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (52 experiments)

Factor Value U/D Experiments
monocyte
2
4
E-MEXP-583, E-MEXP-2019, E-GEOD-11755, E-GEOD-22373, E-GEOD-995, ... (6 experiments)
bronchial epithelial
2
E-AFMX-5, E-MTAB-25
fibroblast
2
E-GEOD-3204, E-GEOD-3920
adult native RPE from 89 y.o. donor
1
E-GEOD-18811
n/a
1
E-MTAB-24
mononuclear cell
1
E-GEOD-7307
90 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-GEOD-1577, E-GEOD-16363, E-MTAB-62, ... (59 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-MTAB-62, E-MEXP-231, E-GEOD-2514, E-MTAB-37
head and neck squamous cell carcinoma
3
E-MTAB-62, E-GEOD-2379, E-GEOD-6631
adenocarcinoma
2
E-MTAB-37, E-MTAB-62
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
prostate carcinoma
1
2
E-MTAB-62, E-MEXP-2034, E-GEOD-96
meningitis infected
1
E-MTAB-62
166 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (25 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
Cxcl12
1
E-GEOD-7307
MIG control
1
E-GEOD-15811
nocodazole
1
E-GEOD-571
2-(3,4,5-trimethoxy-phenylamino)-pyrrolo[2,3-d]pyrimidines
1
E-GEOD-6932
eicosapentaenoic acid
1
E-MEXP-1389
33 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-2191, ... (10 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Date of sample preparation and hybridisation
studied in E-GEOD-22541

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-6236, ... (8 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-2509, ... (9 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7578, E-GEOD-20847, E-MTAB-108, E-MEXP-2340 ... (5 experiments)

Genotype
studied in E-GEOD-1923, E-MEXP-1437, E-GEOD-3494, E-GEOD-2466, E-GEOD-22593, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-13073, E-GEOD-7011, E-GEOD-20504, E-GEOD-22278, E-GEOD-9764, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, E-TABM-15, ... (35 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-512 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84 ... (5 experiments)

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-22309, E-GEOD-21750, E-GEOD-1657

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-21837, E-GEOD-1880, E-GEOD-1343

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-2115, E-GEOD-1703, E-GEOD-12438, E-MEXP-1509, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2508, E-GEOD-2466, E-GEOD-7540, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-13818, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-GEOD-1561, E-GEOD-4922

Processing time: 0.46 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM